External broker reports(aggregated public sources), Wilsons Advisory

Wilsons Advisory

Wilsons has a distinguished history in financial services that spans over 125 years. Today, the group has significant capabilities in private wealth management, corporate finance, research and investment strategy, and institutional sales. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

Clarity Pharmaceuticals Ltd / Equity Bottom-Up

<div><div><div><ul><li>Clarity have announced that their exclusive manufacturing partner, NorthStar Radioisotopes, have successfully completed large scale manufacturing runs of their therapeutic radioisotope, 67- Copper, for use in Clarity’s ongoing clinical trial programs (SeCURE, COMBAT, CL04).</li><li>This is a huge milestone for Clarity and NorthStar with large scale production of this isotope being the key impediment to its development as a therapeutic isotope in years past.</li><li>Novel methods utilizing electron accelerator technology have enabled high purity, large scale 67-Cu isolation, which is critical to enable Clarity’s pipeline development across their prostate (PSMA-avid SeCURE; non- PSMA avid COMBAT) and Neuroblastoma (CL04) programs. </li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Clarity have announced that their exclusive manufacturing partner, NorthStar Radioisotopes, have successfully completed large scale manufacturing runs of their therapeutic radioisotope, 67- Copper, for use in Clarity’s ongoing clinical trial programs (SeCURE, COMBAT, CL04).This is a huge milestone for Clarity and NorthStar with large scale production of this isotope being the key impediment to its development as a therapeutic isotope in years past.Novel methods utilizing electron accelerator technology have enabled high purity, large scale 67-Cu isolation, which is critical to enable Clarity’s pipeline development across their prostate (PSMA-avid SeCURE; non- PSMA avid COMBAT) and Neuroblastoma (CL04) programs. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Clarity Pharmaceuticals (CU6) - 67 Cu Is a Go!